title: Treating Fragile X syndrome with the diuretic bumetanide: a case report.
abstract: We report that daily administration of the diuretic NKCC1 chloride co-transporter, bumetanide, reduces the severity of autism in a 10-year-old Fragile X boy using CARS, ADOS, ABC, RDEG and RRB before and after treatment. In keeping with extensive clinical use of this diuretic, the only side effect was a small hypokalaemia. A double-blind clinical trial is warranted to test the efficacy of bumetanide in FRX.
  
  
  CONCLUSIONS
  This single case report showed an improvement of the scores of each test used after 3 months of treatment. Double-blind clinical trials are warranted to test the efficacy of bumetanide in FRX.
authors: Laboratory of Neurosciences de Brest, University of Bretagne Occidentale, Brest, France.
authors: Eric
authors: E
authors: Lemonnier
authors: Gaëlle
authors: G
authors: Robin
authors: Céline
authors: C
authors: Degrez
authors: Roman
authors: R
authors: Tyzio
authors: Marine
authors: M
authors: Grandgeorge
authors: Yehezkel
authors: Y
authors: Ben-Ari
mesh_terms: D002034:Bumetanide / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002659:Child Development Disorders, Pervasive / Q000150:complications*; D004232:Diuretics / Q000009:adverse effects / Q000627:therapeutic use*; D005600:Fragile X Syndrome / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D007008:Hypokalemia / Q000139:chemically induced; D008297:Male
chemical_list: D004232:Diuretics; D002034:Bumetanide